Pacira BioSciences Management
Management criteria checks 0/4
Pacira BioSciences' CEO is Frank Lee, appointed in Jan 2024, has a tenure of 1.33 years. total yearly compensation is $15.94M, comprised of 5.6% salary and 94.4% bonuses, including company stock and options. directly owns 0.059% of the company’s shares, worth $685.68K. The average tenure of the management team and the board of directors is 1.3 years and 1.6 years respectively.
Key information
Frank Lee
Chief executive officer
US$15.9m
Total compensation
| CEO salary percentage | 5.62% |
| CEO tenure | 1.3yrs |
| CEO ownership | 0.06% |
| Management average tenure | 1.3yrs |
| Board average tenure | 1.6yrs |
Recent management updates
Recent updates
Pacira BioSciences Remains A 'Buy' For Pain Management With The NOPAIN Act
Apr 09Pacira BioSciences, Inc. (NASDAQ:PCRX) Looks Inexpensive But Perhaps Not Attractive Enough
Apr 07
Pacira BioSciences: Back On An Uptrend After Positive Developments
Mar 14Pacira BioSciences (NASDAQ:PCRX) Has A Rock Solid Balance Sheet
Jan 30Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Low P/S No Reason For Excitement
Jan 03Pacira BioSciences: Not Done Yet Despite Devastating Share Price Losses
Nov 25
EXPAREL's Calculated Expansion And Innovative R&D Bolster Market Dominance Amidst Challenges
Sep 24 Expanding EXPAREL utilization in outpatient settings and through GPO partnerships aims to enhance revenue by increasing market penetration and affordability.Pacira BioSciences, Inc. (NASDAQ:PCRX) Not Doing Enough For Some Investors As Its Shares Slump 34%
Sep 06Little Excitement Around Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Revenues As Shares Take 29% Pounding
Jul 23These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Safely
Jun 07Pacira BioSciences, Inc. Just Missed Earnings - But Analysts Have Updated Their Models
May 10Getting In Cheap On Pacira BioSciences, Inc. (NASDAQ:PCRX) Might Be Difficult
May 03Does Pacira BioSciences (NASDAQ:PCRX) Have A Healthy Balance Sheet?
Feb 05Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Low P/S No Reason For Excitement
Jan 05We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt
Nov 03Is Pacira BioSciences (NASDAQ:PCRX) Using Too Much Debt?
Jul 28Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Intrinsic Value Is Potentially 26% Below Its Share Price
Jul 07Is Pacira BioSciences (NASDAQ:PCRX) A Risky Investment?
Apr 18We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt
Dec 28CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$104m |
| Dec 31 2024 | US$16m | US$897k | -US$100m |
Compensation vs Market: Frank's total compensation ($USD15.94M) is above average for companies of similar size in the US market ($USD3.99M).
Compensation vs Earnings: Insufficient data to compare Frank's compensation with company performance.
CEO
Frank Lee (56 yo)
1.3yrs
Tenure
US$15,944,347
Compensation
Mr. Frank D. Lee served as an Independent Director at Bolt Biotherapeutics, Inc. since November 2021 until September 2024. He is Independent Director of Bausch Health Companies Inc. from May 14, 2024. He i...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.3yrs | US$15.94m | 0.059% $ 685.7k | |
| Chief Financial Officer | less than a year | US$3.16m | no data | |
| Principal Accounting Officer & Senior VP of Finance | 13.2yrs | US$2.56m | 0.011% $ 125.0k | |
| Chief Administrative Officer & Secretary | 10.6yrs | US$3.61m | 0% $ 0 | |
| Advisor | 1.3yrs | US$727.38k | 0.51% $ 6.0m | |
| Executive Officer | less than a year | US$1.41m | 0.087% $ 1.0m | |
| Chief Medical Officer | 3.8yrs | US$2.88m | 0.042% $ 491.0k | |
| Head of Investor Relations | no data | no data | no data | |
| Chief Legal & Compliance Officer | 3.4yrs | US$2.05m | no data | |
| Chief Manufacturing Officer | 2.1yrs | no data | no data | |
| Chief Business Officer | less than a year | no data | no data | |
| Chief Commercial Officer | less than a year | no data | no data |
1.3yrs
Average Tenure
53.5yo
Average Age
Experienced Management: PCRX's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.3yrs | US$15.94m | 0.059% $ 685.7k | |
| Independent Chair of the Board | 13.9yrs | US$389.01k | 0.027% $ 309.2k | |
| Independent Director | 11.9yrs | US$390.61k | 0.042% $ 493.5k | |
| Independent Director | 5.7yrs | US$350.01k | 0.011% $ 132.0k | |
| Independent Director | 1.6yrs | US$365.01k | 0% $ 0 | |
| Independent Director | 1.6yrs | US$365.43k | 0.011% $ 123.3k | |
| Independent Director | 1.6yrs | US$362.01k | 0% $ 0 | |
| Independent Director | 7.9yrs | US$374.01k | 0.019% $ 225.2k | |
| Independent Director | 1.6yrs | US$373.97k | 0.0043% $ 50.2k |
1.6yrs
Average Tenure
61yo
Average Age
Experienced Board: PCRX's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/13 18:44 |
| End of Day Share Price | 2025/05/13 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pacira BioSciences, Inc. is covered by 31 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anita Dushyanth | Berenberg |
| Gary Nachman | BMO Capital Markets Equity Research |
| Tazeen Ahmad | BofA Global Research |